BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026
Go back to BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026| (NASDAQ: BBIO) | Delayed: 82.66 +0.21 (0.25%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $82.45 | 52 Week High | $ | |||
| Open | $82.47 | 52 Week Low | $ | |||
| Day High | $82.88 | P/E | N/A | |||
| Day Low | $81.02 | EPS | $ | |||
| Volume | 1,568,958 | |||||
